JP2019531357A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531357A5 JP2019531357A5 JP2019542356A JP2019542356A JP2019531357A5 JP 2019531357 A5 JP2019531357 A5 JP 2019531357A5 JP 2019542356 A JP2019542356 A JP 2019542356A JP 2019542356 A JP2019542356 A JP 2019542356A JP 2019531357 A5 JP2019531357 A5 JP 2019531357A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- rnai agent
- subject
- doses
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022068684A JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2024173304A JP7850215B2 (ja) | 2016-10-18 | 2024-10-02 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2025258789A JP2026062719A (ja) | 2016-10-18 | 2025-12-17 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409816P | 2016-10-18 | 2016-10-18 | |
| US62/409,816 | 2016-10-18 | ||
| US201662422028P | 2016-11-14 | 2016-11-14 | |
| US62/422,028 | 2016-11-14 | ||
| US201762472525P | 2017-03-16 | 2017-03-16 | |
| US62/472,525 | 2017-03-16 | ||
| US201762550426P | 2017-08-25 | 2017-08-25 | |
| US62/550,426 | 2017-08-25 | ||
| PCT/US2017/057218 WO2018075658A1 (en) | 2016-10-18 | 2017-10-18 | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068684A Division JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531357A JP2019531357A (ja) | 2019-10-31 |
| JP2019531357A5 true JP2019531357A5 (enExample) | 2021-10-21 |
| JP7181881B2 JP7181881B2 (ja) | 2022-12-01 |
Family
ID=60388127
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542356A Active JP7181881B2 (ja) | 2016-10-18 | 2017-10-18 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2022068684A Active JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2024173304A Active JP7850215B2 (ja) | 2016-10-18 | 2024-10-02 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2025258789A Pending JP2026062719A (ja) | 2016-10-18 | 2025-12-17 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022068684A Active JP7566815B2 (ja) | 2016-10-18 | 2022-04-19 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2024173304A Active JP7850215B2 (ja) | 2016-10-18 | 2024-10-02 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
| JP2025258789A Pending JP2026062719A (ja) | 2016-10-18 | 2025-12-17 | プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20180104360A1 (enExample) |
| EP (2) | EP3529360B1 (enExample) |
| JP (4) | JP7181881B2 (enExample) |
| KR (3) | KR20240067272A (enExample) |
| CN (4) | CN119345221A (enExample) |
| AU (3) | AU2017346879B2 (enExample) |
| CA (1) | CA3042423A1 (enExample) |
| CL (1) | CL2019001047A1 (enExample) |
| DK (1) | DK3529360T3 (enExample) |
| ES (1) | ES2982911T3 (enExample) |
| FI (1) | FI3529360T3 (enExample) |
| HR (1) | HRP20240930T1 (enExample) |
| HU (1) | HUE067712T2 (enExample) |
| IL (1) | IL266066A (enExample) |
| LT (1) | LT3529360T (enExample) |
| MX (2) | MX2019004573A (enExample) |
| PL (1) | PL3529360T3 (enExample) |
| PT (1) | PT3529360T (enExample) |
| RS (1) | RS65725B1 (enExample) |
| SI (1) | SI3529360T1 (enExample) |
| WO (1) | WO2018075658A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015013105B1 (pt) | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| EP3340994A1 (en) | 2015-08-25 | 2018-07-04 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder |
| HRP20240930T1 (hr) | 2016-10-18 | 2024-10-11 | Novartis Ag | Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9) |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| CN118291456A (zh) | 2017-12-01 | 2024-07-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7360716B2 (ja) | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | ｓｉＲＮＡ複合体及びその調製方法と使用 |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| CN113286888B (zh) * | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US20230183694A1 (en) | 2020-03-16 | 2023-06-15 | Argonaute RNA Limited | Antagonist of pcsk9 |
| CN115572726A (zh) * | 2021-06-21 | 2023-01-06 | 上海君实生物医药科技股份有限公司 | 一种抑制PCSK9基因表达的siRNA及其用途 |
| WO2023241591A1 (zh) * | 2022-06-14 | 2023-12-21 | 大睿生物医药科技(上海)有限公司 | 调控PCSK9基因活性的siRNA分子 |
| JP2025531341A (ja) * | 2022-09-19 | 2025-09-19 | カイロンノヴァ （シャーメン） バイオファーマ カンパニー，リミテッド | 炭水化物－オリゴヌクレオチド複合体、薬物組成物および治療への応用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7605251B2 (en) * | 2006-05-11 | 2009-10-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
| BR112015013105B1 (pt) * | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| EP3340994A1 (en) * | 2015-08-25 | 2018-07-04 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder |
| HRP20240930T1 (hr) | 2016-10-18 | 2024-10-11 | Novartis Ag | Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9) |
-
2017
- 2017-10-18 HR HRP20240930TT patent/HRP20240930T1/hr unknown
- 2017-10-18 RS RS20240774A patent/RS65725B1/sr unknown
- 2017-10-18 US US15/787,405 patent/US20180104360A1/en not_active Abandoned
- 2017-10-18 CN CN202411481996.2A patent/CN119345221A/zh active Pending
- 2017-10-18 CN CN201780077941.7A patent/CN110088283A/zh not_active Withdrawn
- 2017-10-18 AU AU2017346879A patent/AU2017346879B2/en active Active
- 2017-10-18 LT LTEPPCT/US2017/057218T patent/LT3529360T/lt unknown
- 2017-10-18 ES ES17800976T patent/ES2982911T3/es active Active
- 2017-10-18 KR KR1020247014347A patent/KR20240067272A/ko not_active Ceased
- 2017-10-18 CN CN202411482008.6A patent/CN119700800A/zh active Pending
- 2017-10-18 DK DK17800976.7T patent/DK3529360T3/da active
- 2017-10-18 FI FIEP17800976.7T patent/FI3529360T3/fi active
- 2017-10-18 JP JP2019542356A patent/JP7181881B2/ja active Active
- 2017-10-18 PL PL17800976.7T patent/PL3529360T3/pl unknown
- 2017-10-18 EP EP17800976.7A patent/EP3529360B1/en active Active
- 2017-10-18 CN CN202411479127.6A patent/CN119318663A/zh active Pending
- 2017-10-18 MX MX2019004573A patent/MX2019004573A/es unknown
- 2017-10-18 SI SI201731532T patent/SI3529360T1/sl unknown
- 2017-10-18 KR KR1020257038513A patent/KR20250171391A/ko active Pending
- 2017-10-18 CA CA3042423A patent/CA3042423A1/en active Pending
- 2017-10-18 WO PCT/US2017/057218 patent/WO2018075658A1/en not_active Ceased
- 2017-10-18 KR KR1020197014059A patent/KR20190077411A/ko not_active Ceased
- 2017-10-18 PT PT178009767T patent/PT3529360T/pt unknown
- 2017-10-18 HU HUE17800976A patent/HUE067712T2/hu unknown
- 2017-10-18 EP EP24170268.7A patent/EP4397311A3/en active Pending
-
2019
- 2019-04-16 IL IL266066A patent/IL266066A/en unknown
- 2019-04-17 CL CL2019001047A patent/CL2019001047A1/es unknown
- 2019-04-17 MX MX2024004495A patent/MX2024004495A/es unknown
-
2020
- 2020-06-22 US US16/908,517 patent/US20210093736A1/en active Pending
-
2022
- 2022-04-19 JP JP2022068684A patent/JP7566815B2/ja active Active
-
2023
- 2023-11-09 AU AU2023263519A patent/AU2023263519B2/en active Active
-
2024
- 2024-10-02 JP JP2024173304A patent/JP7850215B2/ja active Active
-
2025
- 2025-12-17 JP JP2025258789A patent/JP2026062719A/ja active Pending
- 2025-12-22 US US19/429,048 patent/US20260108631A1/en active Pending
-
2026
- 2026-05-11 AU AU2026203584A patent/AU2026203584A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3529360T3 (fi) | Menetelmiä sydän- ja verisuonitapahtumien ennaltaehkäisemiseksi proproteiini-konvertaasi-subtilisiini-keksiini tyyppi 9 (pcsk9) -proteiinia vähentämällä | |
| Pistolesi et al. | A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy | |
| Hörl | Iron therapy for renal anemia: how much needed, how much harmful? | |
| JP2025504863A5 (enExample) | ||
| JP2023549115A5 (enExample) | ||
| JP2019504112A5 (enExample) | ||
| Smith et al. | Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime | |
| JP2018087228A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| JP2019206562A5 (enExample) | ||
| JP2019518028A5 (enExample) | ||
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| Perkins et al. | No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis? | |
| Goldenberg et al. | Managing the course of kidney disease in adults with type 2 diabetes: from the old to the new | |
| Leitch et al. | Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy | |
| JP7221956B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| Goldberg | Novel therapies and new targets of treatment for familial hypercholesterolemia | |
| CN115120724A (zh) | 治疗再生障碍性贫血的方法和药物组合物 | |
| KR20250054795A (ko) | Angptl3-관련 질환 및 장애의 치료 방법 | |
| Sanchez et al. | Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease | |
| Zhang et al. | The use of nicardipine for electroconvulsive therapy: a dose-ranging study | |
| Littlewood et al. | The use of intravenous iron in patients with cancer‐related anaemia | |
| Heinz et al. | A new spectrophotometric assay for enzymes of purine metabolism | |
| Qunibi | Is it too much of a good thing? A new era in phosphate binder therapy in ESRD | |
| Lucarelli et al. | Hematopoietic cell transplantation for thalassemia | |
| Veys et al. | Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS) |